Russia's Cancer Vaccine Enteromix Displays 100 Per Cent Efficacy In Clinical Trials

Last Updated:September 06, 2025, 23:11 IST

Enteromix, a personalized mRNA cancer vaccine, showed 100% efficacy and safety in trials. Developed by Russian institutes, it awaits Ministry of Health approval for public use.

With trials completed successfully, the only remaining step is regulatory clearance. (AI-generated pic)

In what could be a ground-breaking achievement in the fight against cancer, a revolutionary mRNA-based vaccine named Enteromix has demonstrated 100% efficacy and safety in its completed clinical trials.

The treatment, which targets and destroys cancer cells while significantly shrinking large tumours, is now awaiting final approval from the Ministry of Health before it can be made available to the public, RT India reported.

Developed using cutting-edge mRNA technology — similar to that used in Covid-19 vaccines — Enteromix works by training the immune system to recognize and eliminate cancer cells. Unlike traditional treatments such as chemotherapy or radiation, the vaccine is personalized for each patient, making it a tailored approach to cancer therapy.

No serious side effects were reported, and patients tolerated the treatment well.

Earlier, it was announced that Russia had started clinical trials of the new EnteroMix oncolytic vaccine with 48 volunteers participating. The drug was developed by the Russian Ministry of Health’s National Medical Research Radiological Centre in collaboration with the Engelhardt Institute of Molecular Biology (EIMB) of the Russian Academy of Sciences (RAS).

With trials completed successfully, the only remaining step is regulatory clearance. The Ministry of Health is expected to conduct a final review of the data in the coming weeks.

If approved, Enteromix could become the first personalized mRNA cancer vaccine available to the public, potentially transforming the landscape of oncology and offering new hope to millions.

Manisha Roy

Manisha Roy is a Senior Sub-Editor at News18.com's general desk. She comes with an experience of over 5 years in media industry. She covers politics and other hard news. She can be contacted at Manisha.Roy@nw18...Read More

Manisha Roy is a Senior Sub-Editor at News18.com's general desk. She comes with an experience of over 5 years in media industry. She covers politics and other hard news. She can be contacted at Manisha.Roy@nw18...

Read More

News world Russia's Cancer Vaccine Enteromix Displays 100 Per Cent Efficacy In Clinical Trials

Read More